We observed a significant lowering effect of marine-derived n-3 PUFAs supplementation on fasting blood level of CRP; the pooled effect size was −0.54 (95% CI, −0.72 to −0.35; P = 0.000) (Figure 13), and the percentage of change (in geometric mean) was −41.73% (95% CI, −51.32% to −29.53%); no heterogeneity was observed in these studies (I2 = 0.0%); one study recruited both subjects with chronic non-autoimmune disease and subjects with chronic autoimmune disease [45], and after excluding this study the pooled effect size still remain significant. Here, CRP is linked to autoimmune disease.